LOTUS PHARMACEUTICAL CO., LTD. Financials Lotus Pharmaceutical Co., Ltd. Taipei Exchange
Equities
1795
TW0001795003
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 108 TWD | +0.47% |
|
-4.42% | -.--% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 27,958 | 19,628 | 25,569 | 64,462 | 71,935 | 75,902 | - |
| Enterprise Value (EV) 1 | 33,440 | 23,614 | 29,450 | 71,231 | 71,935 | 81,615 | 77,465 |
| P/E ratio | 42 x | 19 x | 17.8 x | 21.2 x | 17.3 x | 15.5 x | 12.7 x |
| Yield | - | - | 1.98% | 1.41% | - | 1.86% | 2.61% |
| Capitalization / Revenue | 3.05 x | 1.83 x | 2.02 x | 4.41 x | 4.24 x | 4.03 x | 3.58 x |
| EV / Revenue | 3.64 x | 2.2 x | 2.33 x | 4.87 x | 4.24 x | 4.34 x | 3.65 x |
| EV / EBITDA | 19.7 x | 10.2 x | 9.64 x | 14.1 x | 11.8 x | 11.7 x | 9.6 x |
| EV / FCF | -1,095 x | 15.4 x | -65 x | 22.7 x | - | 20 x | 15.7 x |
| FCF Yield | -0.09% | 6.5% | -1.54% | 4.41% | - | 4.99% | 6.36% |
| Price to Book | 3.61 x | 2.24 x | 2.31 x | 4.62 x | - | 3.69 x | 2.72 x |
| Nbr of stocks (in thousands) | 243,114 | 245,354 | 262,246 | 262,041 | 264,468 | 264,468 | - |
| Reference price 2 | 115.0 | 80.00 | 97.50 | 246.0 | 272.0 | 287.0 | 287.0 |
| Announcement Date | 19/03/20 | 26/03/21 | 16/03/22 | 14/03/23 | 15/03/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,175 | 10,729 | 12,649 | 14,633 | 16,958 | 18,818 | 21,202 |
| EBITDA 1 | 1,700 | 2,322 | 3,054 | 5,048 | 6,114 | 6,970 | 8,067 |
| EBIT 1 | 1,113 | 1,613 | 2,295 | 4,111 | 4,903 | 6,083 | 7,161 |
| Operating Margin | 12.13% | 15.03% | 18.14% | 28.1% | 28.91% | 32.33% | 33.77% |
| Earnings before Tax (EBT) 1 | 876.4 | 1,304 | 1,870 | 3,940 | 5,103 | 6,063 | 7,886 |
| Net income 1 | 662.8 | 1,030 | 1,403 | 3,021 | 4,106 | 4,844 | 6,201 |
| Net margin | 7.22% | 9.6% | 11.09% | 20.64% | 24.21% | 25.74% | 29.25% |
| EPS 2 | 2.740 | 4.220 | 5.470 | 11.59 | 15.72 | 18.51 | 22.61 |
| Free Cash Flow 1 | -30.53 | 1,535 | -453.1 | 3,142 | - | 4,077 | 4,926 |
| FCF margin | -0.33% | 14.31% | -3.58% | 21.47% | - | 21.66% | 23.24% |
| FCF Conversion (EBITDA) | - | 66.09% | - | 62.25% | - | 58.49% | 61.07% |
| FCF Conversion (Net income) | - | 149.07% | - | 104.02% | - | 84.16% | 79.44% |
| Dividend per Share 2 | - | - | 1.930 | 3.460 | - | 5.347 | 7.500 |
| Announcement Date | 19/03/20 | 26/03/21 | 16/03/22 | 14/03/23 | 15/03/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,803 | 3,161 | 2,910 | 5,389 | 3,172 | 4,524 | 4,442 | 4,573 | 3,419 | 4,198 | 5,100 | 5,253 | 4,234 | 4,864 | 4,776 |
| EBITDA 1 | 586.7 | 832.5 | 730.4 | 2,881 | - | 1,964 | 1,908 | 1,775 | 469.5 | 1,572 | 1,979 | 2,126 | 982 | - | - |
| EBIT 1 | 392.5 | 623.5 | 490.2 | 2,641 | 356.3 | 1,664 | 1,614 | 1,482 | 143.4 | 1,256 | 1,852 | 1,933 | 1,095 | 1,766 | 1,736 |
| Operating Margin | 14% | 19.72% | 16.84% | 49.01% | 11.24% | 36.78% | 36.33% | 32.41% | 4.19% | 29.91% | 36.32% | 36.8% | 25.85% | 36.31% | 36.35% |
| Earnings before Tax (EBT) 1 | 320.2 | 588.6 | 426.8 | 2,630 | 294.8 | 1,505 | 1,524 | 1,566 | 508.2 | 1,306 | 1,840 | 1,948 | 1,123 | 1,729 | 1,703 |
| Net income 1 | 251.3 | 446.1 | 327.7 | 2,079 | 167.6 | 1,194 | 1,266 | 1,246 | 400 | 1,036 | 1,451 | 1,530 | 877.2 | 1,351 | 1,316 |
| Net margin | 8.96% | 14.11% | 11.26% | 38.58% | 5.28% | 26.39% | 28.5% | 27.24% | 11.7% | 24.68% | 28.45% | 29.13% | 20.72% | 27.78% | 27.55% |
| EPS 2 | 0.9500 | 1.710 | 1.250 | 7.930 | 0.6300 | 4.550 | 4.840 | 4.760 | 1.530 | 3.940 | 5.550 | 5.852 | 3.350 | 5.100 | 4.970 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 16/03/22 | 13/05/22 | 11/08/22 | 10/11/22 | 14/03/23 | 15/05/23 | 11/08/23 | 10/11/23 | 15/03/24 | 11/05/24 | - | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 5,482 | 3,986 | 3,881 | 6,769 | - | 5,713 | 1,563 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.225 x | 1.716 x | 1.271 x | 1.341 x | - | 0.8197 x | 0.1937 x |
| Free Cash Flow 1 | -30.5 | 1,535 | -453 | 3,142 | - | 4,077 | 4,927 |
| ROE (net income / shareholders' equity) | 8.86% | 12.5% | 14.2% | 24.2% | - | 23.8% | 24% |
| ROA (Net income/ Total Assets) | 4.05% | 5.43% | 6.85% | 11.9% | - | 13.4% | 13.9% |
| Assets 1 | 16,386 | 18,974 | 20,482 | 25,374 | - | 36,049 | 44,667 |
| Book Value Per Share 2 | 31.80 | 35.60 | 42.10 | 53.20 | - | 77.70 | 105.0 |
| Cash Flow per Share 2 | 1.250 | 7.990 | 0.4700 | 14.30 | - | 21.40 | 28.20 |
| Capex 1 | 333 | 414 | 573 | 577 | - | 500 | 494 |
| Capex / Sales | 3.63% | 3.86% | 4.53% | 3.94% | - | 2.66% | 2.33% |
| Announcement Date | 19/03/20 | 26/03/21 | 16/03/22 | 14/03/23 | 15/03/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
287
TWD
Average target price
390.2
TWD
Spread / Average Target
+35.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B |
- Stock Market
- Equities
- 1795 Stock
- 1795 Stock
- Financials Lotus Pharmaceutical Co., Ltd.
